Table of Contents Author Guidelines Submit a Manuscript
Malaria Research and Treatment
Volume 2017 (2017), Article ID 3958765, 8 pages
https://doi.org/10.1155/2017/3958765
Clinical Study

Sustained Effectiveness of a Fixed-Dose Combination of Artesunate and Amodiaquine in 480 Patients with Uncomplicated Plasmodium falciparum Malaria in Côte d’Ivoire

1Institut Pierre Richet (IPR)/Institut National de Santé Publique (INSP), Bouaké, Côte d’Ivoire
2National Malaria Control Programme, Abidjan, Côte d’Ivoire
3Infectious and Tropical Diseases Unit, Treichville University Hospital, Abidjan, Côte d’Ivoire
4Infectious and Tropical Diseases Department, Bouaké University Hospital, Bouaké, Côte d’Ivoire
5Institut Pasteur de Côte d’Ivoire, Unité de Paludologie, Abidjan, Côte d’Ivoire
6Diagnostic and Research Center on AIDS and Other Infectious Diseases (CeDReS), Abidjan, Côte d’Ivoire
7Pharmacovigilance Unit, Medical Sciences, Felix Houphouët-Boigny, Abidjan, Côte d’Ivoire
8Medicines for Malaria Venture, Geneva, Switzerland
9Sanofi Access to Medicines, Gentilly, France

Correspondence should be addressed to Serge Brice Assi; rf.oohay@igresissa

Received 8 June 2017; Accepted 10 October 2017; Published 7 December 2017

Academic Editor: Ananias Escalante

Copyright © 2017 Serge Brice Assi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. J. White, S. Pukrittayakamee, and T. T. Hien, “Malaria,” The Lancet, vol. 383, no. 9918, pp. 723–735, 2013. View at Publisher · View at Google Scholar
  2. World Health Organization, Guidelines for the Treatment of Malaria, WHO Press, Geneva, Switzerland, 2006.
  3. World Health Organization, Ed., Guidelines for the Treatment of Malaria, WHO Press, Geneva, Switzerland, 3rd edition, 2015.
  4. S. M. Taylor, C. M. Parobek, D. K. DeConti et al., “Absence of putative artemisinin resistance mutations among Plasmodium falciparum in Sub-Saharan Africa: a molecular epidemiologic study,” The Journal of Infectious Diseases, vol. 211, no. 5, pp. 680–688, 2015. View at Publisher · View at Google Scholar
  5. M. D. Conrad, V. Bigira, J. Kapisi et al., “Polymorphisms in K13 and falcipain-2 associated with artemisinin resistance are not prevalent in Plasmodium falciparum isolated from Ugandan children,” PLoS ONE, vol. 9, no. 8, article e105690, 2014. View at Publisher · View at Google Scholar
  6. E. A. Ashley, M. Dhorda, R. M. Fairhurst et al., “Spread of artemisinin resistance in Plasmodium falciparum malaria,” The New England Journal of Medicine, vol. 371, no. 5, pp. 411–423, 2014. View at Google Scholar
  7. F. Ariey, B. Witkowski, C. Amaratunga et al., “A molecular marker of artemisinin-resistant Plasmodium falciparum malaria,” Nature, vol. 505, no. 7481, pp. 50–55, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Lemnge, M. Alifrangis, M. Y. Kafuye et al., “High reinfection rate and treatment failures in children treated with amodiaquine for falciparum malaria in Muheza villages, northeastern Tanzania,” The American Journal of Tropical Medicine and Hygiene, vol. 75, no. 2, pp. 188–193, 2006. View at Google Scholar · View at Scopus
  9. F. L. Eyase, H. M. Akala, L. Ingasia et al., “The Role of Pfmdr1 and Pfcrt in changing Chloroquine, Amodiaquine, Mefloquine and Lumefantrine susceptibility in Western-Kenya P. falciparum samples during 2008–2011,” PLoS ONE, vol. 8, no. 5, article e64299, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. A. O. Talisuna, C. Karema, B. Ogutu et al., “Mitigating the threat of artemisinin resistance in Africa: Improvement of drug-resistance surveillance and response systems,” The Lancet Infectious Diseases, vol. 12, no. 11, pp. 888–895, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Griffin, “New once a day, fixed dose antimalarial is now available for adults and children,” BMJ (Clinical research ed.), vol. 334, no. 7591, article 443, 2007. View at Google Scholar · View at Scopus
  12. J.-F. Faucher, A. Aubouy, A. Adeothy et al., “Comparison of sulfadoxine-pyrimethamine, unsupervised artemether- lumefantrine, and unsupervised artesunate-amodiaquine fixed-dose formulation for uncomplicated Plasmodium falciparum malaria in Benin: A randomized effectiveness noninferiority trial,” The Journal of Infectious Diseases, vol. 200, no. 1, pp. 57–65, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. J. L. Ndiaye, M. Randrianarivelojosia, I. Sagara et al., “Randomized, multicentre assessment of the efficacy and safety of ASAQ a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria,” Malaria Journal, vol. 8, no. 1, article 125, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. S. B. Sirima, A. B. Tiono, A. Gansané et al., “The efficacy and safety of a new fixed-dose combination of amodiaquine and artesunate in young African children with acute uncomplicated Plasmodium falciparum,” Malaria Journal, vol. 8, no. 1, article 48, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. J.-L. A. Ndiaye, B. Faye, A. Gueye et al., “Repeated treatment of recurrent uncomplicated Plasmodium falciparum malaria in Senegal with fixed-dose artesunate plus amodiaquine versus fixed-dose artemether plus lumefantrine: A randomized, open-label trial,” Malaria Journal, vol. 10, article 237, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. The Four Artemisinin-Based Combinations (4ABC) Study Group, “A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in african children: a randomized trial,” PLoS Medicine, vol. 8, no. 11, article e1001119, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. B. Schramm, P. Valeh, E. Baudin et al., “Efficacy of artesunate-amodiaquine and Artemether-Lumefantrine fixed-dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria among children aged six to 59 months in Nimba County, Liberia: an open-label randomized non-inferiority trial,” Malaria Journal, vol. 12, article 251, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. B. Schramm, P. Valeh, E. Baudin et al., “Tolerability and safety of artesunate-amodiaquine and artemether- lumefantrine fixed dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria: Two open-label, randomized trials in Nimba County, Liberia,” Malaria Journal, vol. 12, no. 1, article 250, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Yeka, V. Lameyre, K. Afizi et al., “Efficacy and safety of fixed-dose artesunate-amodiaquine vs. artemether-lumefantrine for repeated treatment of uncomplicated malaria in Ugandan children,” PLoS ONE, vol. 9, no. 12, article e113311, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. F. Bompart, J.-R. Kiechel, R. Sebbag, and B. Pecoul, “Innovative public-private partnerships to maximize the delivery of anti-malarial medicines: Lessons learned from the ASAQ Winthrop experience,” Malaria Journal, vol. 10, article 143, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. S.-B. Assi, Y. T. Aba, J. C. Yavo et al., “Safety of a fixed-dose combination of artesunate and amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in real-life conditions of use in Côte d’Ivoire,” Malaria Journal, vol. 16, no. 1, pp. 1–12, 2017. View at Publisher · View at Google Scholar · View at Scopus
  22. World Health Organization, Methods for Surveillance of Antimalarial Efficacy, WHO Press, Geneva, Switzerland, 2009.
  23. World Health Organization, Assessment and Monitoring of Antimalarial Drug Efficacy for the Treatment of Uncomplicated Falciparum Malaria, WHO Press, Geneva, Switzerland, 2003.
  24. World Health Organization, Methods and Techniques for Clinical Trials on Antimalarial Drug Efficacy: Genotyping to Identify Parasite Populations, WHO Press, Geneva, Switzerland, 2008.
  25. E. Espié, A. Lima, B. Atua et al., “Efficacy of fixed-dose combination artesunate-amodiaquine versus artemether-lumefantrine for uncomplicated childhood Plasmodium falciparum malaria in Democratic Republic of Congo: A randomized non-inferiority trial,” Malaria Journal, vol. 11, article 174, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. G. O. Gbotosho, A. Sowunmi, C. T. Happi, and T. M. Okuboyejo, “Therapeutic efficacies of artemisinin-based combination therapies in nigerian children with uncomplicated falciparum malaria during five years of adoption as first-line treatments,” The American Journal of Tropical Medicine and Hygiene, vol. 84, no. 6, pp. 936–943, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Shayo, C. I. Mandara, F. Shahada, J. Buza, M. M. Lemnge, and D. S. Ishengoma, “Therapeutic efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in North-Eastern Tanzania,” Malaria Journal, vol. 13, no. 1, article 376, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. World Health Organization, Methods for Surveillance of Antimalarial Drug Efficacy, WHO, Geneva, Switzerland, 2009.
  29. O. A. Toure, S. B. Assi, T. L. N'Guessan et al., “Open-label, randomized, non-inferiority clinical trial of artesunate-Amodiaquine versus artemetherlumefantrine fixed-dose combinations in children and adults with uncomplicated falciparum malaria in Côte d'Ivoire,” Malaria Journal, vol. 13, no. 1, article 439, 2014. View at Publisher · View at Google Scholar · View at Scopus